{"title":"Blocking of CDC25B suppresses sarcoma progression via arresting cell cycle.","authors":"Renqin Lin, Jianhua Lin","doi":"10.21037/tcr-2024-2328","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Soft tissue sarcoma is a malignant tumor originating from mesenchymal tissue, accounting for approximately 1% of adult malignancies. Cell division cycle protein 25B (CDC25B) plays a crucial role in human diseases, however, its function in soft tissue sarcoma remains poorly understood. This study aims to explore the prognostic and therapeutic values of CDC25B in sarcoma.</p><p><strong>Methods: </strong>The expression and prognostic values of CDC25B in sarcoma were analyzed using bioinformatics approaches. Additionally, a CDC25B inhibitor (CDC25B-IN-1) was used to evaluate the potential therapeutic value of the CDC25B target using Cell Counting Kit-8 (CCK-8), quantitative polymerase chain reaction (qPCR) detection, 5-ethynyl-2'-deoxyuridine (EdU), colony formation, transwell, wound healing, flow cytometry and western blot (WB) assays.</p><p><strong>Results: </strong>The bioinformatics analysis found that CDC25B is overexpressed in sarcoma tissues, and high expression of CDC25B correlated with lower disease-specific survival (DSS), progress-free interval (PFI), and overall survival (OS). The univariate and multivariate analysis identified CDC25B as an independent prognostic biomarker in sarcoma. Experimental validation demonstrated that blocking CDC25B using CDC25B inhibitor (CDC25B-IN-1) can suppress sarcoma progression by inducing G2 cell cycle arrest.</p><p><strong>Conclusions: </strong>CDC25B is highly expressed in sarcoma, and blocking of CDC25B can suppress sarcoma progression by inducing G2 cell cycle arrest. These findings suggest that CDC25B may serve as a potential molecular biomarker and therapeutic target for sarcoma.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 6","pages":"3438-3451"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268883/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2024-2328","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Soft tissue sarcoma is a malignant tumor originating from mesenchymal tissue, accounting for approximately 1% of adult malignancies. Cell division cycle protein 25B (CDC25B) plays a crucial role in human diseases, however, its function in soft tissue sarcoma remains poorly understood. This study aims to explore the prognostic and therapeutic values of CDC25B in sarcoma.
Methods: The expression and prognostic values of CDC25B in sarcoma were analyzed using bioinformatics approaches. Additionally, a CDC25B inhibitor (CDC25B-IN-1) was used to evaluate the potential therapeutic value of the CDC25B target using Cell Counting Kit-8 (CCK-8), quantitative polymerase chain reaction (qPCR) detection, 5-ethynyl-2'-deoxyuridine (EdU), colony formation, transwell, wound healing, flow cytometry and western blot (WB) assays.
Results: The bioinformatics analysis found that CDC25B is overexpressed in sarcoma tissues, and high expression of CDC25B correlated with lower disease-specific survival (DSS), progress-free interval (PFI), and overall survival (OS). The univariate and multivariate analysis identified CDC25B as an independent prognostic biomarker in sarcoma. Experimental validation demonstrated that blocking CDC25B using CDC25B inhibitor (CDC25B-IN-1) can suppress sarcoma progression by inducing G2 cell cycle arrest.
Conclusions: CDC25B is highly expressed in sarcoma, and blocking of CDC25B can suppress sarcoma progression by inducing G2 cell cycle arrest. These findings suggest that CDC25B may serve as a potential molecular biomarker and therapeutic target for sarcoma.
背景：软组织肉瘤是一种起源于间质组织的恶性肿瘤，约占成人恶性肿瘤的1%。细胞分裂周期蛋白25B （CDC25B）在人类疾病中起着至关重要的作用，然而，其在软组织肉瘤中的功能尚不清楚。本研究旨在探讨CDC25B在肉瘤中的预后和治疗价值。方法：应用生物信息学方法分析CDC25B在肉瘤中的表达及预后价值。此外，使用CDC25B抑制剂（CDC25B- in -1）通过细胞计数试剂盒-8 （CCK-8）、定量聚合酶链反应（qPCR）检测、5-乙基-2'-脱氧尿苷（EdU）、菌落形成、transwell、伤口愈合、流式细胞术和western blot （WB）检测来评估CDC25B靶点的潜在治疗价值。结果：生物信息学分析发现，CDC25B在肉瘤组织中过表达，CDC25B高表达与较低的疾病特异性生存期（DSS）、无进展间期（PFI）和总生存期（OS）相关。单因素和多因素分析确定CDC25B是肉瘤的独立预后生物标志物。实验验证表明，使用CDC25B抑制剂（CDC25B- in -1）阻断CDC25B可以通过诱导G2细胞周期阻滞来抑制肉瘤的进展。结论：CDC25B在肉瘤中高表达，阻断CDC25B可通过诱导G2细胞周期阻滞抑制肉瘤进展。这些发现提示CDC25B可能作为肉瘤的潜在分子生物标志物和治疗靶点。
期刊介绍：
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
